Microbot Medical Inc.
MBOTHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Microbot Medical Inc. (MBOT) is listed under Medical Devices. At a $65.4M market cap, Microbot Medical Inc. ranks as a micro-cap company within healthcare. The company offers LIBERTY, an endovascular robotic surgical system designed to maneuver guidewires and over-the-wire devices, such as microcatheters within the body's vasculature for use in cardiovascular, peripheral, endovascular, and neurovascular operations.
Market Cap
$65.4M
Beta
1.05
P/E (TTM)
—
P/E (Fwd)
-3.04
EPS (TTM)
$-0.25
EPS (Fwd)
$-0.32
ROE
-32.9%
ROA
-21.7%
Cash
$67.4M
Total Debt
$876,000
Free CF
-$14.2M
52W Change
-59.4%
Annual Financials
Cash vs Debt
Where MBOT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, MBOT finished 47.51% below its 150-day moving average ($1.81) and 50.00% below its 200-day moving average ($1.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MBOT overbought or oversold?
At the October 20, 2026 close, MBOT's RSI(14) was 12.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $67.4M in cash and $876K in debt, MBOT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$14.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -32.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, MBOT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Microbot Medical Inc.'s trajectory.